Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/31/2005WO2005027929A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
03/31/2005WO2005027928A1 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
03/31/2005WO2005027927A1 2-alkylidene-19-nor-vitamin d derivatives for enhancement of peak bone mass in adolescence
03/31/2005WO2005027926A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bone morphogenetic protein
03/31/2005WO2005027925A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
03/31/2005WO2005027924A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005WO2005027923A1 Use of vitamin d3 analogue for the treatment of benign prostatic hyperplasia
03/31/2005WO2005027922A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause
03/31/2005WO2005027921A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
03/31/2005WO2005027920A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
03/31/2005WO2005027919A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
03/31/2005WO2005027918A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
03/31/2005WO2005027917A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
03/31/2005WO2005027916A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
03/31/2005WO2005027915A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/31/2005WO2005027914A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
03/31/2005WO2005027913A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
03/31/2005WO2005027912A1 Steroidal quinols and their use for estrogen replacement therapy
03/31/2005WO2005027911A1 Hormone concentrate pharmaceutical compositon
03/31/2005WO2005027910A1 Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
03/31/2005WO2005027909A1 Cephem compounds
03/31/2005WO2005027908A1 Compounds useful as motilin agonists and method
03/31/2005WO2005027907A1 Use of chk1 inhibitors to control cell proliferation
03/31/2005WO2005027906A1 Transscleral delivery
03/31/2005WO2005027905A1 Pharmaceutical compositions for the treatment of organophosphate poisoning
03/31/2005WO2005027904A1 Hair restorer
03/31/2005WO2005027903A1 Polyether brevetoxin derivatives as a treatment for neurotoxic shellfish poisoning and ciguatera fish poisoning
03/31/2005WO2005027902A1 MODULATORS OF Cdk9 AS A THERAPEUTIC TARGET IN CARDIAC HYPERTROPHY
03/31/2005WO2005027901A1 Compositions and methods using same for treating amyloid-associated diseases
03/31/2005WO2005027899A1 Use of fumaric acid derivatives for the prophylaxis and treatment of genome damage
03/31/2005WO2005027898A1 Amino acid compositions
03/31/2005WO2005027897A1 Nutritional supplement and protocol
03/31/2005WO2005027896A1 Concurrent drugs
03/31/2005WO2005027895A2 Thyroid hormone analogs and methods of use in angiogenesis
03/31/2005WO2005027894A1 Enhanced method of treatment of growth disorders
03/31/2005WO2005027893A1 HUMAN β-DEFENSIN SECRETION PROMOTER
03/31/2005WO2005027892A1 Early insulin secretion promoter
03/31/2005WO2005027891A1 Accelerator for initial insulin secretion
03/31/2005WO2005027890A1 Modafinil modified release pharmaceutical compositions
03/31/2005WO2005027889A1 Visceral pain dulling composition
03/31/2005WO2005027888A1 Use of the effective constituents from rhubarb for the manufacture of a medicament for the enhancement of as2 o3 induced apoptosis
03/31/2005WO2005027887A2 Methods and compositions for improving endothelial function
03/31/2005WO2005027886A2 Methods of preventing or treating recurrence of myocardial infarction
03/31/2005WO2005027885A2 Composition and method for treating bezoar and trichobezoar
03/31/2005WO2005027884A2 Stabilized ocular solutions
03/31/2005WO2005027883A1 Gsk-3 beta inhibitors in the treatment of bone-related diseases
03/31/2005WO2005027882A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
03/31/2005WO2005027881A2 Stable quinapril compositions
03/31/2005WO2005027880A1 Enteric soft gelatin capsule containing esomeprazole and method of preparation
03/31/2005WO2005027876A1 Pharmaceutical compositions of benzimidazole and processes for their preparation
03/31/2005WO2005027873A2 Therapeutic aminoglycoside-containing hydrogel nanoparticles
03/31/2005WO2005027872A2 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
03/31/2005WO2005027870A1 Buccal formulations of galanthamine and uses thereof
03/31/2005WO2005027866A1 Use of licocalchone a or of an extract containing licocalchone a from radix glycyrrhizae inflatae against skin aging
03/31/2005WO2005027855A2 Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
03/31/2005WO2005027850A2 Treating or preventing restless legs syndrome using prodrugs of gaba analogs
03/31/2005WO2005027848A2 Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
03/31/2005WO2005027843A2 Chronotherapeutic dosage forms
03/31/2005WO2005027842A2 Combinations of drugs for the treatment of neoplasms
03/31/2005WO2005027839A2 Methods and reagents for the treatment of immunoinflammatory disorders
03/31/2005WO2005027838A2 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
03/31/2005WO2005027832A2 Edta containing compositions and uses thereof
03/31/2005WO2005027826A2 Methods and treating severe acute respiratory syndrome
03/31/2005WO2005027824A2 Cyclic bis-compounds clearing malformed proteins
03/31/2005WO2005027823A2 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
03/31/2005WO2005027807A1 Pharmaceutical delivery system
03/31/2005WO2005027719A2 Methods and systems for identifying predisposition to the placebo effect
03/31/2005WO2005027663A2 Compositions comprising oligosaccharides
03/31/2005WO2005027661A1 Compositions for the treatment and prevention of diabetes mellitus
03/31/2005WO2005027656A1 Functional sweetener
03/31/2005WO2005027639A1 Control of protozoa and protozoan cysts that harbor legionella
03/31/2005WO2005027637A1 Compounds useful as motilin agonists and method
03/31/2005WO2005027636A2 Improved topical treatment for the eradication and/or control of ectoparasites
03/31/2005WO2005014007B1 Compounds for the treatment of autoimmune and demyelinating diseases
03/31/2005WO2005011636A3 Spray drying processes for forming solid amorphous dispersions of drugs and polymers
03/31/2005WO2005011565A3 Antimycosic nail varnish
03/31/2005WO2005009961A3 Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
03/31/2005WO2005009947A3 Aryl heteroaromatic products, compositions comprising the same and use thereof
03/31/2005WO2005007862A3 Methionine recovery processes
03/31/2005WO2005007102A3 Phytochemicals for the treatment of mastalgia, endometriosis and hpv-related conditions including cervical dysplasia
03/31/2005WO2005005632A3 SMALL INTERFERING RNA SPECIFIC TO SUB-UNITS $G(A), $G(A)' AND $G(B) OF THE KINASE PROTEIN CK2, AND THE APPLICATIONS OF THE SAME
03/31/2005WO2005004862A3 Method for photodynamic inactivation of pathogens using ala
03/31/2005WO2005003064A3 Sulfonamide substituted imidazoquinolines
03/31/2005WO2005002600A3 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus
03/31/2005WO2005002520A3 Ophthalmic compositions for treating ocular hypertension
03/31/2005WO2005002482A8 Transdermal hormone delivery system: compositions and methods
03/31/2005WO2004113270A3 Propionic acid derivatives useful in the treatment of lipid disorders
03/31/2005WO2004112829A3 Compositions and methods for the diagnosis and treatment of tumors of glial origin
03/31/2005WO2004112776A3 Inflammatory disease treatment
03/31/2005WO2004112696A3 Methods and compositions for delivery of catecholic butanes for treatment of diseases
03/31/2005WO2004111253A3 Polyvalent metal-substituted starch products
03/31/2005WO2004110371A3 Method for the treatment of malignancies
03/31/2005WO2004110338A3 Methods of treating obesity and related disorders using tellurium and selenium compounds
03/31/2005WO2004108666A3 Neuroprotective benzoate and benzamide compounds
03/31/2005WO2004108141A3 Bach-o-protein coupled receptor releated methods
03/31/2005WO2004108133A3 Modulators of vr1 receptor
03/31/2005WO2004108092A3 Tannate compositions and methods of use
03/31/2005WO2004108086A3 HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
03/31/2005WO2004105688A3 Bactericidal composition and associated method
03/31/2005WO2004103973A8 Phenyl quinolines and their use as estrogen receptor modulators
1 ... 4734 4735 4736 4737 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 ... 7860